Create accountLogin

Recent searches

No recent searches

Search options

Only available when logged in.
mastodon.world is one of the many independent Mastodon servers you can use to participate in the fediverse.
Generic Mastodon server for anyone to use.

Administered by:

Server stats:

12K
active users

mastodon.world: AboutStatusProfiles directoryPrivacy policy

Mastodon: AboutGet the appKeyboard shortcutsView source codev4.3.6

#clinicalresearch

0 posts0 participants0 posts today
Public
Alessia Visconti

📣 Hot from the press, a new preprint from the lab: medrxiv.org/content/10.1101/20 📣

We asked 47 experts in clinical research and decision-making processes about the actual use of #patient preference information and the challenges of their integration

Bad news: current use is limited
Good news: virtually everyone would likely use them

Btw, I've just done the wrap up: M. di Blasio*'s did all the heavy lifting, and our mastermind @berkeley devised it!

#ClinicalResearch

*Not on the Fediverse yet

medRxiv · Exploring Patient Preference Information in Clinical Research and Decision Models: An Investigative SurveyBackground. There is an increasingly acknowledged role for patients in decision-making processes: this involvement extends to defining care pathways, assessing care quality and advancing healthcare technologies. Patient preferences play a pivotal role in this context, particularly when multiple therapeutic options lack clear distinctions in efficacy. Methods. To investigate the use of patient preference information, we conducted an online survey targeting 46 experts in clinical research, pharmaceutical industry, regulatory affairs, and health technology assessment. The survey included questions about the frequency of using patient preference information, perceptions of the benefits and challenges of integrating them in decision making, as well as the availability of such data within their respective organizations. Results Patient preference information is routinely used by about 30% of the respondents, who highlighted various challenges and technical difficulties for a more widespread adoption, such as limited patient engagement, difficulty in obtaining reliable preference, and resistance to deviating from traditional practices. Despite this, we observed that about 90% of the respondents is likely to prioritize integrating patient preference information in their future research or decision-making processes. Conclusion There is a growing recognition of the potential benefits of adopting a more patient-centric approach to promote a more effective, equitable, and patient-focused healthcare system, but concerted efforts and investments are necessary to support this effort. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This work was partially supported by "NODES Spoke 5 project" no ECS00000036, which has received funding from MUR-M4C2 1.5 of PNRR (code BERP\_PNRR\_EI\_23\_01\_F). This work was partially supported by the "Proof of Value Instrument 2022 Initiative" (S1921\_POV_D218) funded by Compagnia San Paolo and University of Turin. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethics committee of the University of Turin (Comitato di Bioetica d'Ateneo) waived ethical approval for this work (Protocol number 0722874). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data collected during the study are available to bona fide researchers under managed access due to governance constraints, and can be requested to the corresponding author.
Continued thread
Public
John Hobbs

6/6
In conclusion, N-Acetyl D-Glucosamine emerges as a formidable ally in the quest for maintaining a vigorous and resilient body. While research continues to evolve, the existing evidence illuminates the significant, tangible benefits of incorporating NAG into one's health strategy, always under professional advisement.

#HealthInnovation#ClinicalResearch#NAG
Continued thread
Public
John Hobbs

6/6
In conclusion, N-Acetyl D-Glucosamine emerges as a formidable ally in the quest for maintaining a vigorous and resilient body. While research continues to evolve, the existing evidence illuminates the significant, tangible benefits of incorporating NAG into one's health strategy, always under professional advisement.

#HealthInnovation#ClinicalResearch#NAG
Public *
Dana Foundation

The newly launched Collective to Strengthen Pathways for Health Research (spearheaded by the Doris Duke Foundation) is soliciting proposals to host symposia across the US in spring 2025 to explore and demonstrate how strengthening support for prevention of and improvement in clinical encounters can maximize the societal benefits of research. Organizations with 501(c)(3) status are eligible to apply. #neurosociety #neuroscience #clinicalresearch

dana.org/article/philanthropic

Dana FoundationPhilanthropic Collective Aims to Improve Disease Prevention and Care
Public
R Consortium

🌱 A new R community is blooming in Ahmedabad, India! The Ahmedabad R User Group (ARUG), led by the experienced Sanket Sinojia, is focused on clinical research and pharmaceutical industries. "ARUG is all about fostering collaboration, knowledge-sharing, and mentorship," says Sanket. 🌟

Learn more in our latest blog: r-consortium.org/blog/2024/08/

#RStats #Pharma #ClinicalResearch

ExploreLive feeds
About